Bristol Myers shows power of Opdivo-Yervoy combo in first-line colorectal cancer subset

More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnosed patients. But another approval may have to wait.